![]() | |
Names | |
---|---|
Preferred IUPAC name
(5aR,11bS)-2-Propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]quinoline-9,10-diol | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C18H21NO2S | |
Molar mass | 315.429 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist.[1][2] It was developed as a possible treatment for Parkinson's disease,[3] as well as for other applications such as treatment of cocaine addiction,[4][5] but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued.[6][7] It has mainly been used as its diacetate ester prodrug adrogolide (ABT-431), which has better bioavailability.[8][9]
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |